316 related articles for article (PubMed ID: 24857106)
21. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
22. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
23. Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review.
Badal SAM; Aiken WD; Chin SN
Curr Drug Targets; 2017; 18(10):1204-1213. PubMed ID: 27138755
[TBL] [Abstract][Full Text] [Related]
24. Investigational MET inhibitors to treat Renal cell carcinoma.
Nandagopal L; Sonpavde GP; Agarwal N
Expert Opin Investig Drugs; 2019 Oct; 28(10):851-860. PubMed ID: 31554440
[No Abstract] [Full Text] [Related]
25. Emerging therapeutics in refractory renal cell carcinoma.
Koshkin VS; Rini BI
Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
[TBL] [Abstract][Full Text] [Related]
26. Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma.
Cardenas LM; Deluce JE; Khan S; Gulam O; Maleki Vareki S; Fernandes R; Lalani AA
Curr Oncol; 2022 Jul; 29(8):5426-5441. PubMed ID: 36005167
[TBL] [Abstract][Full Text] [Related]
27. Resistance to targeted therapy in renal-cell carcinoma.
Rini BI; Atkins MB
Lancet Oncol; 2009 Oct; 10(10):992-1000. PubMed ID: 19796751
[TBL] [Abstract][Full Text] [Related]
28. A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.
Figlin RA
Immunotherapy; 2014; 6(3):261-8. PubMed ID: 24354908
[TBL] [Abstract][Full Text] [Related]
29. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
Carlo MI; Voss MH; Motzer RJ
Nat Rev Urol; 2016 Jul; 13(7):420-31. PubMed ID: 27324121
[TBL] [Abstract][Full Text] [Related]
30. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).
Atkins MB; Philips GK
Expert Opin Emerg Drugs; 2016 Sep; 21(3):243-54. PubMed ID: 27539246
[TBL] [Abstract][Full Text] [Related]
31. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
Costa LJ; Drabkin HA
Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Gollob JA
Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
[TBL] [Abstract][Full Text] [Related]
33. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.
Rini BI; McDermott DF; Hammers H; Bro W; Bukowski RM; Faba B; Faba J; Figlin RA; Hutson T; Jonasch E; Joseph RW; Leibovich BC; Olencki T; Pantuck AJ; Quinn DI; Seery V; Voss MH; Wood CG; Wood LS; Atkins MB
J Immunother Cancer; 2016; 4():81. PubMed ID: 27891227
[TBL] [Abstract][Full Text] [Related]
34. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
35. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
Su D; Singer EA; Srinivasan R
Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
[TBL] [Abstract][Full Text] [Related]
36. [Not Available].
Mery B; Jones S; Vallard A; Rowinski E; Guillot A; Magné N
Bull Cancer; 2018 Dec; 105 Suppl 3():S235-S241. PubMed ID: 30595152
[TBL] [Abstract][Full Text] [Related]
37. Targeted agents for the treatment of advanced renal cell carcinoma.
Stadler WM
Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
[TBL] [Abstract][Full Text] [Related]
38. The role of targeted therapy in metastatic renal cell carcinoma.
Unnithan J; Rini BI
ScientificWorldJournal; 2007 Mar; 7():800-7. PubMed ID: 17619763
[TBL] [Abstract][Full Text] [Related]
39. Renal cell carcinoma: molecular biology and targeted therapy.
Su D; Stamatakis L; Singer EA; Srinivasan R
Curr Opin Oncol; 2014 May; 26(3):321-7. PubMed ID: 24675233
[TBL] [Abstract][Full Text] [Related]
40. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
Flaherty KT; Puzanov I
Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]